{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:12:12Z","timestamp":1792390332034,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.colsurfb.2016.08.048","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T20:29:26Z","timestamp":1472848166000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo studies"],"prefix":"10.1016","volume":"148","author":[{"given":"Sohail","family":"Akhter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ahsan","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Zaki","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseem","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan Jalees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2016.08.048_bib0005","first-page":"1","article-title":"Synthesis and characterization of poly (2-hydroxyethylmethacrylate) contact lenses containing chitosan nanoparticles as an ocular delivery system for dexamethasone sodium phosphate","author":"Behl","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0010","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3109\/03639045.2015.1066798","article-title":"Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time","volume":"41","author":"Fabiano","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijbiomac.2015.11.070","article-title":"Chitosan-based nanoparticles for rosmarinic acid ocular delivery-in vitro tests","volume":"84","author":"da Silva","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0020","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.05-0495","article-title":"Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance","volume":"47","author":"Enriquez de Salamanca","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2016.02.039","article-title":"Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): in vivo, in vitro and ex vivo studies","volume":"502","author":"Fangueiro","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jfb6020277","article-title":"Nanomedicine approaches for corneal diseases","volume":"6","author":"Chaurasia","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2015.02.019","article-title":"Nanotherapies for the treatment of ocular diseases","volume":"95","author":"Reimondez-Troitino","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jphp.12132","article-title":"Topical delivery of ocular therapeutics: carrier systems and physical methods","volume":"66","author":"Souza","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0045","doi-asserted-by":"crossref","first-page":"604204","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","article-title":"Topical ophthalmic cyclosporine: pharmacology and clinical uses","volume":"54","author":"Donnenfeld","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00003226-199007000-00002","article-title":"Update on topical cyclosporin A. Background, immunology, and pharmacology","volume":"9","author":"Belin","year":"1990","journal-title":"Cornea"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye (London, England)"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0070","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/bjo.86.9.988","article-title":"Systemic cyclosporin A in high failure risk, repeated corneal transplantation","volume":"86","author":"Rumelt","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0075","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-010-1388-8","article-title":"Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial","volume":"248","author":"Sinha","year":"2010","journal-title":"Geaefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0085","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.ophtha.2006.05.022","article-title":"Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes","volume":"113","author":"Price","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12274-014-0547-3","article-title":"Phenylboronic acid modified mucoadhesive nanoparticle drug carriers facilitate weekly treatment of experimentallyinduced dry eye syndrome","volume":"8","author":"Liu","year":"2015","journal-title":"Nano Res."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/ejnm-2013-0012","article-title":"Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits","volume":"5","author":"Akhter","year":"2013","journal-title":"Eur. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0100","first-page":"159","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface","volume":"224","author":"De Campos","year":"2001","journal-title":"Appl. Cyclosporin A: Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijbiomac.2016.04.070","article-title":"Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone","volume":"89","author":"Kalam","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.drudis.2016.04.002","article-title":"Modern approaches to the ocular delivery of cyclosporine A","volume":"21","author":"Agarwal","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/2230-973X.177823","article-title":"Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: improved permeation, retention, and penetration","volume":"6","author":"Abdullah","year":"2016","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0120","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","article-title":"Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery","volume":"17","author":"Prosperi-Porta","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2009.07.015","article-title":"Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization","volume":"380","author":"Elnaggar","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/157341308786306071","article-title":"Investigation of nanoemulsion system for transdermal delivery of domperidone: ex-vivo and in vivo studies","volume":"4","author":"Akhter","year":"2008","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.colsurfa.2014.04.008","article-title":"Effect of oil and co-surfactant on the formation of solutol HS 15 based colloidal drug carrier by box\u2013behnken statistical design","volume":"453","author":"Ahmad","year":"2014","journal-title":"Colloids Surf. A"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1166\/jbn.2011.1241","article-title":"Assessment of ocular pharmacokinetics and safety of Ganciclovir loaded nanoformulations","volume":"7","author":"Akhter","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0145","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/jbm.a.34467","article-title":"Part II: enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops","volume":"101","author":"Kalam","year":"2013","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.addr.2012.09.018","article-title":"Microemulsion-based media as novel drug delivery systems","volume":"64","author":"Lawrence","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijpharm.2006.08.038","article-title":"Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil","volume":"329","author":"Date","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1211\/jpp.58.1.0006","article-title":"Effects of transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes","volume":"58","author":"Liu","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0165","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1248\/bpb.32.1266","article-title":"Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid","volume":"32","author":"Yamaguchi","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00917068","article-title":"Relationship between precorneal retention of viscous eye drops and tear fluid composition","volume":"16","author":"Ludwig","year":"1992","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2016.08.048_bib0175","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.ijbiomac.2014.10.014","article-title":"Amphotericin-B entrapped lecithin\/chitosan nanoparticles for prolonged ocular application","volume":"72","author":"Chhonker","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"issue":"194848","key":"10.1016\/j.colsurfb.2016.08.048_bib0180","article-title":"An overview on dry eye treatment: approaches for cyclosporin a delivery","volume":"2012","author":"Yavuz","year":"2012","journal-title":"Sci. World J."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776516306245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776516306245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T03:43:05Z","timestamp":1556595785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776516306245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":36,"alternative-id":["S0927776516306245"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2016.08.048","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo studies","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2016.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}